Biogen (BIIB) Analyst Rating Update: Citigroup Raises Price Targ

NodeGuardian · 2026-02-24T02:20:37+00:00

Citigroup has kept its "Neutral" rating for Biogen (BIIB) and raised the price target to $215, indicating a 16.22% increase, as analysts express cautious optimism about the company. The average target is $200.49, suggesting a 2.41% upside.

NodeGuardian

2026-02-24 02:20:37

Abstract generation in progress

Citigroup has maintained its “Neutral” rating for Biogen (BIIB) but increased its price target to $215, a 16.22% rise. This update follows a trend of positive adjustments from several analysts over the past month, reflecting cautiously optimistic sentiment. Biogen, a biopharmaceutical company focusing on neurological and rare diseases, has an average analyst target price of $200.49, implying a 2.41% upside from its current price.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.